AXGN · Axogen, Inc.

Track AXGN — free

$41.92 -0.52 (-1.23%) At close · Sep 30

Russell 2000 member Rebalance outlook locked

Market Cap

$2.28B

53.76M

Volume · Sep 30 1.09M Avg daily vol (3M) 1.18M

Up next

Next earnings call

Oct 26, 2026 Est · unconfirmed · in 4 wks

Latest filing: 10-Q

filed Jul 29, 2026

Q2 2026 earnings call transcript

call held Jul 29, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$251.17M

Trailing 12 months

Net income (TTM)

−$33.55M

Trailing 12 months

Revenue growth YoY

+23.1%

Year over year

Operating margin

-5.1%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

0.4%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+11.2%

Year over year · more shares

Price change (1Y)

+145.9%

Trailing year

Short interest

7.5%

Latest settlement · 2.9 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Jul 29, 2026

Q2 FY26

TL;DR. Axogen reported Q2 revenue of $69.7M, up 23.1% YoY, and raised full-year 2026 revenue growth guidance to at least 24% (≥$279M), while lowering full-year gross margin guidance to at least 73% due to unfavorable breast-related product mix.

Bullish

+ Q2 revenue grew 23.1% YoY to $69.7M, with breast growth of over 50% YoY driving broad-based strength across all target markets.
+ Year-to-date active surgeon count increased by more than 210, exceeding plan, and high-potential account productivity grew 20% YoY.

Bearish

− Full-year 2026 gross margin guidance was lowered to at least 73%, below the prior plan, driven by unfavorable breast product mix.
− GAAP net loss was $1.5M ($0.03/share) versus net income of $0.6M ($0.01/share) in Q2 2025, and operating expenses rose to 75.8% of revenue, up 4.6 percentage points YoY.
− Adjusted EBITDA margin compressed to 12.1% from 16.3% in Q2 2025, a 4.2 percentage point decline.
− Aetna coverage decision remains pending despite historical timing expectations, creating uncertainty on near-term commercial coverage expansion to ~95% of lives.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Sell Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 16.3 · calm Equity put/call 0.53

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg +8%

above

Price vs 50-day avg −8%

below

RSI (14) 38

neutral

MACD trend Negative

52-week position 73%

mid-range

Momentum

relative strength

Strong

1-month return −16%

trailing

6-month return +27%

trailing

YTD return +28%

this year

Relative strength +14%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $46 › 200d $39 — 50d above 200d

Institutional flow Accumulating

+14% holders QoQ · +52 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

7.54% of float · ▲ +6.5% MoM · 2.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

254 holders — near 3-yr high, broad support

Squeeze score 63

elevated · 0–100

Fundamentals

Strong

Revenue growth +20%

Y/Y

Gross margin 74%

contracting

EPS growth −48%

Y/Y

Free cash flow $-2.9M

Balance sheet $24.2M

net cash

Quant / Vol

risk profile

Very High

Volatility 55%

annualized · 1-yr

Max drawdown −19%

past year

ATR 5.0%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 4 of last 4

Latest guidance · from the 8-K filed Jul 29, 2026

For 2026, full-year

Full-year revenue Initiated at least $279M

prior FY $225.21M midpoint +23.9% Y/Y

Revenue growth Initiated at least 24%

Gross margin Initiated at least 73%

2026

Gross margin of at least 73% at least 73%

Guided vs delivered · last 4 settled

Annual revenue 2024 Financial Guidance

guided $182M – $186M

guided $182M – $186M $187.34M Beat +1.8%

Full-year 2023 revenue full year 2023

guided $154M – $159M

guided $154M – $159M $159.01M Beat +1.6%

Full year revenue full year 2022

guided $135M – $142M

guided $135M – $142M $138.58M In line

Full-year 2021 revenue full-year 2021

guided $127M – $129M

guided $127M – $129M $127.36M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell

2 · 3 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+8% Bullish

Price vs 50-day avg

−8% Bearish

RSI (14)

38 Neutral

MACD trend

Negative Bearish

52-week position

73% Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $46 › 200d $39 — 50d above 200d

Institutional flow Accumulating

+14% holders QoQ · +52 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

7.54% of float · ▲ +6.5% MoM · 2.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

254 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $16 Now $42 · 73% Range high $52

vs 200-day avg +8% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Devices — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
AXGN Axogen, Inc. this stock	$2.28B	+28.1%	+20.2%	—	7.5%
ABT Abbott Laboratories	$174.90B	-21.1%	+5.7%	28.1	1.1%
MDT Medtronic plc	$113.38B	-9.3%	+8.4%	21.8	1.3%
SYK Stryker Corp	$104.47B	-20.7%	+11.2%	28.2	2.0%
BSX Boston Scientific Corp	$63.59B	-54.0%	+12.5%	17.8	3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

254

% held: 98.0%
Net QoQ: +2.7M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

251

View

Short & Settlement

Short Interest Rising

Shares short

4.1M

Days to cover: 2.9d
Change: +246.1K sh

View

Short Volume

Short vol %

63%

As of: Sep 30, 2026

Short Total

View

Fails to Deliver

FTD shares

95.0K

Value: $4.9M
As of: Aug 27, 2026

View

Off-Exchange

Off-exchange %

42.2%

Week of: Aug 24, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Donna Shalala

Amount: $1.0K–$15.0K
Traded: Jun 24, 2019

View

Financials

Revenue (FY)

$225.2M

Net income (FY): $-15.7M
EPS diluted: $-0.34

View

Filings

SEC Filings

Latest

8-K

Filed: Sep 10, 2026
This year: 13

View

Proposed Sales

Value

$174.6K

Shares: 3.5K
Filed: Sep 2, 2026

View

Earnings & Events

Earnings Calls

Last call

Sep 10, 2026

View

Performance

	5D	20D	120D	MTD	YTD
AXGN	-3.2%	-16.0%	+27.0%	-17.4%	+28.1%
SPY	-1.2%	-0.4%	+13.1%	-0.4%	+12.1%
vs SPY	-2.0%	-15.6%	+13.9%	-17.1%	+16.0%

Key facts CIK 805928 CUSIP 05463X106 13F (30d) 6 filings 6 filers Visit website Investor relations

AXGN · Axogen, Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance